natgillin/translations-raw huggingface dataset:
After reconstitution: 24 hours when stored at 25°C or in a refrigerator (2C – 8C) if kept in the original vial and protected from light.
Po pripravi: 24 ur v primeru shranjevanja pri 25 °C ali v hladilniku (2 C do 8 C), če je zdravilo v originalni viali in zaščiteno pred svetlobo.
After reconstitution: 30 minutes when stored at or below 30° C.
Po pripravi: 30 minut pri shranjevanju pri temperaturi do največ 30 °C.
After reconstitution: chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C. From a microbiological point of view, the reconstituted solution should be diluted immediately.
Po rekonstituciji: dokazano je bilo, da je zdravilo kemično in fizikalno stabilno 24 ur, če se ga shranjuje pri temperaturi od 2°C - 8°C. Z mikrobiološkega stališča je treba raztopino razredčiti takoj po rekonstituciji.
After reconstitution: Chemical and physical in-use stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours at 2°C – 8°C. Chemical and physical stability of the diluted solution in infusion bags is established as 12 hours at 25°C or 24 hours at 2°C – 8°C.
Po rekonstituciji: Kemijska in fizikalna stabilnost pripravljene rekonstituirane raztopine v viali je bila dokazana za 12 ur pri 25 °C in do 48 ur pri 2 °C do 8 °C. Kemijska in fizikalna stabilnost razredčene raztopine v infuzijskih vrečkah je dokazana za 12 ur pri 25 °C ali 24 ur pri 2 °C – 8 °C.
After reconstitution: Store at 2 °C – 8 °C (in a refrigerator).
Po rekonstituciji: shranjujte pri temperaturi med 2 C in 8 C (v hladilniku).
After reconstitution: Store at 2°C – 8°C (in a refrigerator).
Po rekonstituciji: shranjujte pri temperaturi med 2 C in 8 C (v hladilniku).
After reconstitution: Store below 30°C or in refrigerator at 2°C to 8°C. Do not freeze.
Po rekonstituciji: Shranjujte pri temperaturi do 30 °C ali v hladilniku pri 2 °C do 8 °C. Ne zamrzujte.
After reconstitution: Store in a refrigerator (2C – 8C).
Po rekonstituciji shranjujte v hladilniku (2-8 °C).
AFTER RECUVYRA IS APPLIED TO THE DOG.
RECUVYRE PSU.
After removal from the deep freeze, further short term storage is allowed at or below -18°C for no more than 4 weeks.
Po odstranitvi s te temperature je dovoljeno nadaljnje kratkoročno shranjevanje pri temperaturi –18 °C ali manj največ 4 tedne.
After removal from the insulated container, Provenge should be used immediately.
Po odstranitvi iz izoliranega vsebnika je treba zdravilo Provenge uporabiti takoj.
After removal from the refrigerator, if the solution is cloudy, the content must not be injected.
Če je raztopina, ko jo vzamete iz hladilnika motna, vsebine ne smete injicirati.
After removal from the refrigerator, Repatha may be stored at room temperature (up to 25C) in the original carton and must be used within 1 month.
Ko ste zdravilo Repatha vzeli iz hladilnika, ga lahko shranjujete na sobni temperaturi (do 25 C) v originalni škatli in ga morate uporabiti v 1 mesecu.
After removal of the flip-off cap from each vial, using aseptic technique swab the rubber stopper and surrounding surface of the vial containing Xiapex and the vial containing the diluent for reconstitution with sterile alcohol (no other antiseptics should be used).
Ko z vsake viale odstranite dvižno zaporko, z uporabo aseptične tehnike s sterilnim alkoholom (drugih razkužil se ne sme uporabiti) obrišite gumijasti zamašek in površino okoli viale, ki vsebuje zdravilo Xiapex, ter vialo, ki vsebuje vehikel za rekonstitucijo.
After removal of the flip-off cap from each vial, using aseptic technique swab the rubber stopper and surrounding surface of the vial containing Xiapex and the vial containing the diluent for reconstitution with sterile alcohol (no other antiseptics should be used).
Ko z vsake viale odstranite dvižno zaporko, z uporabo aseptične tehnike s sterilnim alkoholom (drugih razkužil se ne sme uporabiti) obrišite gumijasti zanašek in površino okoli viale, ki vsebuje zdravilo Xiapex, ter vialo, ki vsebuje vehikel za rekonstitucijo.
After removing a patch, fold it in half with the sticky sides on the inside and press them together.
Po odstranitvi obliža s kože ga prepognite na pol z lepljivo stranjo navznoter in stisnite.
After removing Actraphane FlexPen from the refrigerator, it is recommended to allow the Actraphane FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Actraphane FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing Actraphane InnoLet from the refrigerator, it is recommended to allow the Actraphane InnoLet to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Actraphane InnoLet vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing Actraphane vial from the refrigerator, it is recommended to allow the Actraphane vial to reach room temperature before resuspending the insulin as instructed for first time use.
Ko vialo zdravila Actraphane vzamete iz hladilnika, jo je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing Mixtard FlexPen from the refrigerator, it is recommended to allow the Mixtard FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Mixtard FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing Mixtard InnoLet from the refrigerator, it is recommended to allow the Mixtard InnoLet to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Mixtard InnoLet vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing Mixtard vial from the refrigerator, it is recommended to allow the Mixtard vial to reach room temperature before resuspending the insulin as instructed for first time use.
Ko vialo zdravila Mixtard vzamete iz hladilnika, jo je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilih za prvo uporabo.
After removing NovoMix 30 FlexPen from the refrigerator, it is recommended to allow NovoMix 30 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 30 FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing NovoMix 30 Penfill from the refrigerator, it is recommended to allow NovoMix 30 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 30 Penfill vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing NovoMix 50 FlexPen from the refrigerator, it is recommended to allow NovoMix 50 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 50 FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing NovoMix 50 Penfill from the refrigerator, it is recommended to allow NovoMix 50 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 50 Penfill vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing NovoMix 70 FlexPen from the refrigerator, it is recommended to allow NovoMix 70 FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 70 FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing NovoMix 70 Penfill from the refrigerator, it is recommended to allow NovoMix 70 Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Potem ko zdravilo NovoMix 70 Penfill vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
After removing Protaphane FlexPen from the refrigerator, it is recommended to allow the Protaphane FlexPen to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Protaphane FlexPen vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
After removing Protaphane InnoLet from the refrigerator, it is recommended to allow the Protaphane InnoLet to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Protaphane InnoLet vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
After removing Protaphane Penfill from the refrigerator, it is recommended to allow the Protaphane Penfill to reach room temperature before resuspending the insulin as instructed for first time use.
Ko zdravilo Protaphane Penfill vzamete iz hladilnika, ga je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
After removing Protaphane vial from the refrigerator, it is recommended to allow the Protaphane vial to reach room temperature before resuspending the insulin as instructed for first time use.
Ko vialo zdravila Protaphane vzamete iz hladilnika, jo je priporočljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
After removing the cap the injection must be started within 5 minutes to prevent the medicine from drying out and blocking the needle.
Po odstranitvi pokrovčka je treba z injiciranjem pričeti v 5 minutah, da preprečimo, da bi se zdravilo izsušilo in zaprlo injekcijsko iglo.
After removing the needle from the syringe, the syringe should be attached to the filter by opening the filter luer connector cap (Figure 1).
Ko iglo snamete z brizge, morate slednjo pritrditi na filter, tako da odprete pokrovček filtrskega luer nastavka (slika 1).
After removing the pen cap, the appearance of the insulin should also be checked:
Po odstranitvi pokrovčka injekcijskega peresnika je treba preveriti videz insulina:
After removing the pen cap, the label on the pen and the insulin reservoir should be checked to make sure it contains the correct insulin.
Ko snamete pokrovček injekcijskega peresnika, preverite nalepko na injekcijskem peresniku in rezervoarju z insulinom in se prepričajte, da vsebuje pravo vrsto insulina.
After removing the pen cap, the label on the pen and the insulin reservoir should be checked to make sure it contains the correct insulin.
Po odstranitvi pokrovčka injekcijskega peresnika je treba preveriti napis na injekcijskem peresniku in insulinskem rezervoarju in se prepričati da vsebuje pravi insulin.
After removing the pre-filled pen from the refrigerator the pre-filled pen should be allowed to reach room temperature by waiting 30 minutes, before injecting ORENCIA.
Po vzetju napolnjenega injekcijskega peresnika iz hladilnika, je treba počakati 30 minut, da se zdravilo ORENCIA segreje na sobno temperaturo in ga šele nato injicirati.
After removing the pre-filled syringe from the refrigerator the pre-filled syringe should be allowed to reach room temperature (18°C to 28C°) by waiting for 25 to 30 minutes, before injecting RoActemra .
Po tem, ko vzamemo napolnjeno injekcijsko brizgo iz hladilnika, jo pustimo 25 do 30 minut, da doseže sobno temperaturo (18 °C do 28 °C), preden zdravilo RoActemra injiciramo.
After removing the pre-filled syringe from the refrigerator the pre-filled syringe should be allowed to reach room temperature by waiting 30 minutes, before injecting ORENCIA.
Po vzetju napolnjene injekcijske brizge iz hladilnika, je treba počakati 30 minut, da se zdravilo ORENCIA segreje na sobno temperaturo in ga šele nato injicirati.
After repeated 127 mg twice daily doses of eliglustat in non-PMs, concomitant administration of repeated 600 mg once daily doses of rifampicin (a strong inducer of CYP3A as well as the efflux transporter P-gp) resulted in an approximately 85% decrease in eliglustat exposure.
Po ponovljenih odmerkih eliglustata 127 mg dvakrat dnevno pri osebah, ki niso bile slabi presnavljalci, je sočasno dajanje ponovljenih odmerkov rifampicina (močnega spodbujevalca encima CYP3A in efluksnega prenašalca P-glikoproteina) 600 mg enkrat dnevno povzročilo približno 85- odstotno znižanje izpostavljenosti eliglustatu.
After repeated administration of osaterone acetate at 0.25 mg/kg/day for 7 days, the factor of accumulation is about 3- 4 without change in the rates of absorption or elimination.
Po ponovljenem odmerjanju osateronijevega acetata z 0,25 mg/kg/dan za 7 dni je akumulacijski faktor okoli 3-4 brez spremembe v hitrosti absorpcije ali izločanja.
After repeated administration, the pharmacokinetics of macitentan are dose-proportional up to and including 30 mg.
Po večkratnem dajanju je farmakokinetika macitentana sorazmerna z odmerkom do in vključno s 30 mg.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5–15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25%%) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5–15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5–15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25%%) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah, vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so prejemale 75 mg klopidogrela na dan.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah,vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so prejemale 75 mg klopidogrela na dan.
After repeated IM injections with 150 to 300 mg ZYPADHERA every two weeks, the 10th to 90th percentile of steady-state plasma concentrations of olanzapine were between 4.2 and 73.2 ng/ml.
Po ponovljenih i. m. injiciranjih z 150 mg do 300 mg zdravila ZYPADHERA vsaka dva tedna, sta bila 10-ti in 90-ti odstotek plazemskih koncentracij olanzapina v stanju dinamičnega ravnovesja med 4, 2 in 73, 2 ng/ ml.
After repeated oral administration, R-diastereomer of telaprevir (30-fold less active), pyrazinoic acid, and a metabolite that underwent reduction at the α-ketoamide bond of telaprevir (not active) were found to be the predominant metabolites of telaprevir.
Po večkratnih peroralnih odmerkih so ugotovili, da sta glavna presnovka telaprevirja njegov R-diastereoizomer (ki je 30-krat manj aktiven), pirazinoična kislina in presnovek, ki je reduciran na α-ketoamidni vezi telaprevirja (in ni aktiven).
After repeated oral administration, steady state is reached after the first dosing and no accumulation occurs in dogs whereas modest accumulation is observed in cats.
Po večkratnem peroralnem dajanju doseže stabilno stanje po prvem odmerku in se pri psih ne kopiči, pri mačkah pa so zasledili zmerno kopičenje.
After repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Po enkratnem in večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira.
After repeated subcutaneous administration of 40 mg once daily and
Po večkratnem subkutanem dajanju odmerka 40 mg oz.
After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose.
Po večkratnem subkutanem dajanju odmerka 40 mg oziroma 1,5 mg/kg enkrat na dan pri zdravih prostovoljcih je stanje dinamičnega ravnovesja doseženo 2. dan, povprečno razmerje izpostavljenosti pa je okoli 15 % večje kot po posamičnem odmerku.
After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Po ponavljajočem zdravljenju z zdravili, ki vsebujejo humani koagulacijski faktor IX, je treba pri bolniku spremljati razvoj nevtralizirajočih protiteles (zaviralcev), ki jih je treba količinsko opredeliti v enotah Bethesda (BU – Bethesda Units) z ustreznim biološkim testiranjem.
After repeated treatment with Nonafact, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Po večkratnem zdravljenju z zdravilom Nonafact moramo bolnike spremljati zaradi razvoja nevtralizirajočih protiteles (inhibitorjev), ki jih količinsko določimo z Bethesda enotami (BE) z uporabo ustreznega biološkega testiranja.
After repeated, once daily subcutaneous doses of 1.5 mg/kg, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48 kg/m2) compared to non-obese control subjects, while Amax is not increased.
Po večkratni subkutani uporabi odmerkov 1,5 mg/kg enkrat na dan je povprečna vrednost AUC aktivnosti anti-Xa v stanju dinamičnega ravnovesja minimalno večja pri debelih prostovoljcih (ITM 30–48 kg/m2) kot pri kontrolnih osebah z normalno telesno maso, vrednost Amax pri tem ni povečana.
After repetitive yearly injections the safety profile of INTANZA is similar to the previous injections.
Po ponovnem vsakoletnem cepljenju je bil profil varnosti cepiva INTANZA podoben prejšnjim injekcijam.
After resolution
Po odpravi
After resuspending, complete all of the following stages of injection without delay.
Po resuspendiranju brez odlašanja opravite vse ostale korake injiciranja.
After resuspension, the fluid must have a uniformly milky appearance.
Po ponovnem suspendiranju mora biti tekočina enakomernega mlečnega videza.
After screwing the push rod into the syringe piston, it is important to turn the push rod an additional ½ turn so that the grey piston rotates freely.
Ko palico za potiskanje navijete na bat brizge, morate palico za potiskanje zaviti še za polovico obrata, tako da se sivi bat prosto obrača.
After section 6 of this leaflet there are Instructions For Use giving you step-by-step instructions on how to mix your medicine and how to inject it.
Poglavju 6 tega navodila sledijo Navodila za uporabo, v katerih je korak za korakom pojasnjeno, kako zmešate zdravilo in kako ga injicirate.
After Simparica is given its activity against ticks and fleas lasts for for at least 5 weeks.
Po prejemu učinkuje zdravilo Simparica proti klopom in bolham najmanj 5 tednov.
After single administration of a 15 micrograms sufentanil sublingual tablet, mean terminal phase half- lives in the range of 6 to 10 hours have been observed.
Po enkratnem dajanju podjezičnih tablet sufentanila v odmerku 15 mikrogramov so poročali o povprečnem končnem razpolovnem času v razponu od 6 do 10 ur.
After single dose administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6- fold increase in AUC and Cmax, respectively.
Pri aplikaciji enkratnih odmerkov v obsegu od 75 do 600 mg dvakratno zvišanje odmerka povzroči 2,3-kratno povečanje AUC in 2,6-kratno zvišanje Cmax.
After single dose administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6-fold increase in AUC and Cmax, respectively.
Pri aplikaciji enkratnih odmerkov v obsegu od 75 do 600 mg dvakratno zvišanje odmerka povzroči 2,3- kratno povečanje AUC in 2,6-kratno zvišanje Cmax.
After single dose oral administration of 14C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively.
Po enojnem peroralnem odmerku 14C-rilpivirina se je povprečno 85 % radioaktivnosti izločilo v blatu in 6,1 % v urinu.
After single dose oral administration of 14C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively.
Po peroralnem odmerjanju enkratnega odmerka s 14C označenega rilpivirina je približno 85% radioaktivnosti mogoče prestreči v blatu, 6,1% pa v urinu.
After single doses food increases the bioavailability (AUC) of rufinamide by approximately 34% and the peak plasma concentration by 56%.
Po enkratnih odmerkih hrana zveča biološko uporabnost (AUC) rufinamida za približno 34 % in najvišjo koncentracijo v plazmi za 56 %.
After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 µg/mL, and 5.0-5.3 µg/mL, respectively.
Po enkratnem ali ponavljajočem se peroralnem odmerku 80 mg enkrat na dan je Cmax približno 2,8-3,2 µg/ml, pri odmerku 120 mg pa 5,0- 5,3 µg/ml.